HSIC Henry Schein Inc. featured news, full reports, and detailed charts
Henry Schein Inc. (HSIC) Wrap Up:
Henry Schein, Inc. distributes healthcare products and services primarily to office-based healthcare practitioners in the North American and European markets. It operates in two segments, Healthcare Distribution and Technology. The Healthcare Distribution segment offers consumable dental products, dental laboratory products, and small equipment, including X-ray products, infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, and abrasives; large dental equipment, such as dental chairs, delivery units and lights, X-ray equipment, equipment repair, and high-tech equipment; medical products, i...Henry Schein Inc. (HSIC:NASDAQ)
Snapshot of Henry Schein Inc. (HSIC)
|
OPEN
$50.89
|
PREVIOUS CLOSE
$51.31
|
|
|
DAY HIGH
$51.43
|
DAY LOW
$50.39
|
|
|
52 WEEK HIGH
10/21/09 - $56.92
|
52 WEEK LOW
11/21/08 - $32.08
|
|
|
MARKET CAP
4.6B
|
AVERAGE VOLUME 3 mo
712.3K
|
|
|
DILUTED EPS TTM
$3.17
|
SHARES OUTSTANDING
90.5M
|
|
|
HSIC Does Not Pay Dividends
|
P/E TTM
16.0x
|
|
| K = Thousands M = Millions B = Billions | ||
related news
HSIC Top Compensated Officers
Executives, Board Directors
Key developments for Henry Schein Inc. (HSIC)
Henry Schein Inc. reported unaudited consolidated earnings results for the third quarter and first nine months ended September 26, 2009. For the quarter, the company reported net income attributable to the company of $96.4 million or $1.05 per diluted share on net sales of $1,659.4 million, operating income of $113.8 million, income from continuing operations attributable to the company of $94.04 million or $1.03 per diluted share, net cash provided by operating activities of $138.8 million, and investments on purchase of fixed assets of $10.01 million compared to net income attributable to the company of $67.4 million or $0.74 per diluted share on net sales of $1,644.2 million, operating income of $115.4 million, income from continuing operations attributable to the company of $67.5 million or $0.74 per diluted share, net cash provided by operating activities of $49.9 million, and investments on purchase of fixed assets of $14.6 million a year ago. Income from continuing operations was $98.3 million against $72.8 million last year. Income from continuing operations before taxes, equity in earnings of affiliates and noncontrolling interests was $113.0 million against $105.5 million last year. The company reported non-GAAP income from continuing operations attributable to the company of $72.9 million or $0.80 per diluted share against non-GAAP income from continuing operations attributable to the company of $70.5 million or $0.77 per diluted share a year ago. Net sales represent an increase of 0.9% compared with the third quarter of 2008. This consists of a 3.1% decline related to foreign currency exchange and a 4.0% growth in local currencies. Excluding sales of seasonal influenza vaccines, which declined from last year's third quarter, net sales increased 3.7%, or 6.9% growth in local currencies. For the nine months, the company reported net income attributable to the company of $224.7 million or $2.48 per diluted share on net sales of $4,752.2 million, operating income of $326.4 million, income from continuing operations attributable to the company of $222.1 million or $2.45 per diluted share, net cash provided by operating activities of $218.3 million, and investments on purchase of fixed assets of $38.4 million compared to net income attributable to the company of $183.4 million or $2 per diluted share on net sales of $4,799.2 million, operating income of $314.8 million, income from continuing operations attributable to the company of $184.2 million or $2 per diluted share, net cash provided by operating activities of $188.6 million, and investments on purchase of fixed assets of $38.1 million a year ago. The company reported non-GAAP income from continuing operations attributable to the company of $203.7 million or $2.25 per diluted share against non-GAAP income from continuing operations attributable to the company of $187.2 million or $2.04 per diluted share a year ago. Income from continuing operations was $237.7 million against $199.9 million last year. Income from continuing operations before taxes, equity in earnings of affiliates and noncontrolling interests was $317.3 million against $294.7 million last year. For the fourth quarter of 2009, the company's diluted EPS attributable to the company is expected to be $0.89 to $0.91. The company updated earnings guidance for the year 2009, the company's diluted EPS attributable to the company is expected to be $3.14 to $3.16 excluding the unusual items. This represents growth of approximately 8% compared with restated 2008 results of $2.92, excluding charges related to the Lehman Brothers bankruptcy as well as restructuring costs. Guidance for 2009 diluted EPS attributable to the company is for current continuing operations including completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any. For the year 2010, the company's diluted EPS attributable to the company is expected to be $3.40 to $3.56, representing growth of 8% to 13% compared with the midpoint of 2009 guidance. Guidance for 2010 diluted EPS attributable to the company is for current continuing operations including completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any.
Henry Schein Inc. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on November 4, 2009).
Henry Schein Inc. said that the company has a strong acquisition pipeline. Steven Paladino, Chief Financial Officer, Executive Vice President and Director of Henry Schein said, “Because today as you’re looking at transactions you have to expense as incurred. So you're expensing items before any acquisitions are completed. So it's a combination of both and it’s just that the activity, as we said recently, the acquisition pipeline continues to be very strong, we continue to see a lot of different opportunities and those expenses or professional fees primarily, in order to evaluate acquisitions have to be expensed when in prior years they were part of purchase price and deferred as purchase price.”
HSIC Competitors
| Company | Last | Change |
| IDEXX Laboratories Inc | $50.73 USD | -0.77 |
| Lincare Holdings | $35.38 USD | +0.57 |
| Omnicare Inc | $23.25 USD | -0.26 |
| Owens & Minor Inc | $39.03 USD | -0.46 |
| Patterson Companies Inc | $25.87 USD | -0.34 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | HSIC | Industry Range |
| Price/Earnings | 16.0x |
|
| Price/Sales | 0.7x |
|
| Price/Book | 2.3x |
|
| Price/Cash Flow | 16.3x |
|
| TEV/Sales | 0.6x |
|
|
HSIC |
||
HSIC transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
